A Novel Role for CD55 in Granulocyte Homeostasis and Anti-Bacterial Host Defense

Henrike Veninga, Robert M. Hoek, Alex F. de Vos, Alex M. de Bruin, Feng-Qi An, Tom van der Poll, René A. W. van Lier, M. Edward Medof, Jörg Hamann

1 Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 2 Center for Experimental Molecular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 3 Institute of Pathology, Case Western Reserve University, Cleveland, Ohio, United States of America

Abstract

Background: In addition to its complement-regulating activity, CD55 is a ligand of the adhesion class G protein-coupled receptor CD97; however, the relevance of this interaction has remained elusive. We previously showed that mice lacking a functional CD97 gene have increased numbers of granulocytes.

Methodology/Results: Here, we demonstrate that CD55-deficient mice display a comparable phenotype with about two-fold more circulating granulocytes in the blood stream, the margined pool, and the spleen. This granulocytosis was independent of increased complement activity. Augmented numbers of Gr-1-positive cells in cell cycle in the bone marrow indicated a higher granulopoietic activity in mice lacking either CD55 or CD97. Concomitant with the increase in blood granulocyte numbers, C55+/mice challenged with the respiratory pathogen Streptococcus pneumoniae developed less bacteremia and died later after infection.

Conclusions: Collectively, these data suggest that complement-independent interaction of CD55 with CD97 is functionally relevant and involved in granulocyte homeostasis and host defense.

Introduction

Decay-accelerating factor (CD55) is a GPI-anchored molecule on leukocytes, erythrocytes, and serum-exposed stromal cells that accelerates the decay of the complement convertases C3 and C5 [1,2]. The importance of CD55 for preventing endogenous cells from unwanted complement activation is evident from the phenotype of CD55-deficient mice that develop exaggerated autoimmune reactions in a variety of spontaneous and induced models [3–8]. Furthermore, studies in CD55−/− mice showed that complement activation not only facilitates innate immune responses but also adaptive immunity [9–13]. Next to the well-established function as regulator of the complement cascade, CD55 is engaged in complement-independent processes and is hijacked by several viral and bacterial pathogens to promote cell adhesion and invasion [14,15]. Furthermore, we demonstrated previously that CD55 is a binding partner of CD97 [16].

CD97 is a member of the EGF-TM7 family of adhesion class G protein-coupled receptors (GPCRs), abundantly expressed by virtually all immune cells [17–22]. Like most adhesion GPCRs, CD97 is a two-subunit molecule consisting of an extracellular α subunit that is non-covalently associated with a seven-transmembrane (TM7) β subunit [19]. At the N-terminus, CD97 possesses tandemly arranged epidermal growth factor (EGF)-like domains of which the first two interact with the N-terminal short consensus repeats (SCR) of CD55 [23–25]. We recently found that CD97 expression levels on leukocytes are increased significantly and reversibly in CD55 knockout mice, proving for the first time that both molecules interact in vivo (manuscript in preparation). The physiological consequences of the interaction between CD55 and CD97 are still poorly understood. A notable finding in mice lacking a functional CD97 gene was a raise in granulocyte numbers in the periphery [26,27]. To explore whether this phenotype was due to abrogation of the CD97-CD55 interaction, we studied the size and functionality of the granulocyte compartments in CD55-deficient mice. We found that CD55-deficient mice, like mice that lack CD97, had increased levels of circulating granulocytes, which was due to a higher granulopoietic activity in the bone marrow. Furthermore, mice lacking CD55 were better protected against S. pneumoniae-induced pneumonia. Together, our data indicate a role for the interaction between CD55 and the adhesion GPCR CD97 in granulocyte homeostasis and host defense.

Materials and Methods

Mice

Mice deficient for CD55 (CD55−/−, synonym: Daf1−/−) and CD97 (CD97−/−) have been generated previously by us [27,28]. Mice...
lacking the receptors for C3a (C3αR)/ and C5a (C5αR) were kind gifts of Prof. Craig Gerard (Harvard Medical School, Boston, MA, USA). Compound mice were created by crossing Cd55-/- mice with C9H7-/-, C3αR-/-, and C5αR-/- mice [11]. All genetically modified mice were back-crossed to C57BL/6 for at least eight generations. C57BL/6 wild-type mice were littermates or were purchased from Charles River (Maasstricht, The Netherlands). Congenic mice expressed Cd97-/-, Cd45-/- mice with C5ar1-/-, and C5a (-/-) as described previously [27]. Briefly, S. pneumoniae serotype 3 was obtained from American Type Culture Collection (ATCC 6303; Rockville, MD, USA). Pneumococci were grown for 6 h to mid-logarithmic phase at 37°C in 5% CO2 using Todd-Hewitt broth (DiIco, Detroit, MI, USA), harvested by centrifugation at 1500 x g for 15 min, and washed twice in sterile isotonic saline. Bacteria were then resuspended in sterile isotonic saline at a concentration of approximately 9 x 10^6 colony-forming units (CFU)/50 μl as determined by plating serial 10-fold dilutions on sheep blood agar plates. Mice were lightly anesthetized and inoculated intranasally (i.n.) with 50 μl.

At 24 h and 48 h after inoculation, mice were anesthetized and sacrificed by heart puncture. Blood was collected in EDTA-containing tubes, and lungs and spleen were harvested in sterile saline. One lung lobe was fixed in 10% formalin and embedded in paraffin. 4-μm sections were cut and stained with hematoxylin and eosin (H&E) and analyzed by a pathologist who was blinded for groups. The other lung lobe and spleen were homogenized at 4°C in four volumes of sterile saline using a tissue homogenizer (BioSpec Products, Bartlesville, OK, USA). CFU were determined from serial dilutions of lung and spleen homogenates and blood, plated on blood agar plates and incubated at 37°C at 5% CO2 for 16 h before colonies were counted. For cytokine and chemokine measurements, lung homogenates were diluted 1:2 in lysis buffer containing 300 mM NaCl, 30 mM Tris, 2 mM MgCl2, 2 mM CaCl2, 1% Triton X-100, and pepstatin A, leupeptin, and aprotinin (all 20 mg/ml; pH 7.4) and incubated at 4°C for 30 min. Homogenates were centrifuged at 1500 x g at 4°C for 15 min, and supernatants were stored at -20°C until assays were performed. Cytokines (TNF, IL-1β) and chemokines (KC, macrophage-inflammatory protein-2 (MIP-2)) were measured using specific ELISA (R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions. Myeloperoxidase levels were quantified by MPO ELISA (Hbt, Uden, The Netherlands) according to the manufacturer’s protocol. In a separate group of mice, survival was monitored.

**Thioglycollate-induced peritonitis**

Sterile peritonitis was induced by i.p. injection of 1 ml 4% aged thioglycollate broth (Sigma-Aldrich). After 4 h, peritoneal lavages were performed with 4 ml ice-cold 2 mM EDTA in PBS. Peritoneal cells were counted on a CASY cell counter (Scharfe, Reutlingen, Germany) and analyzed for cellular composition by flow cytometry.
Statistical analysis

Differences between groups were calculated by unpaired t-test or Mann-Whitney \( U \) test. For comparison of multiple groups one-way ANOVA with Bonferroni’s multiple comparison test was used. The effect of lack of CD55 on the number of BrdU-positive granulocytes in circulation was assessed by calculating the cumulative area under the curve, followed by the Wilcoxon rank-sum test. For survival analysis, Kaplan-Meier analysis followed by log rank test was performed. A two-tailed \( p \) value of less than 0.05 was considered to represent a significant difference.

Results

Mice lacking CD55 have increased levels of circulating granulocytes

CD97-deficient mice display a mild granulocytosis [26,27]. When we analyzed the hematopoietic compartment in \( Cd55^{-/-} \) mice, we found a comparable phenotype (Figure 1A+B). The percentage and absolute number of CD11b\(^+\)Ly6G\(^+\) granulocytes was increased in the blood of about half and in the spleen of almost all mice lacking CD55. In bone marrow, the increase in mature granulocyte (CD11b\(^+\)Gr-1\(^{hi}\)) numbers was less pronounced. There were no differences in the amount of CD11b\(^+\)Gr-1\(^{lo}\) cells, which according to Ueda et al. [33] represent immature precursors of granulocytes. Next to granulocytes, we did observe an increased amount of monocytes in the blood of mice lacking CD55; yet, this was not consistent and not clearly found in spleens of these mice.

The striking similarity between \( Cd55^{-/-} \) and \( Cd97^{-/-} \) mice with respect to granulocyte numbers led us to compare them side-by-side in combination with compound mice, lacking both genes. We found a comparable increase in the percentage and absolute number of granulocytes in \( Cd55^{-/-} \) and \( Cd97^{-/-} \) mice that was not further increased in double knockout \( Cd55^{-/-}Cd97^{-/-} \) mice (Figure 2A).

Increased local production of C3a and C5a and subsequently increased C3a and C5a receptor signaling in \( Cd55^{-/-} \) mice has been shown to be involved in T-cell survival [11]. Furthermore, C5a has been demonstrated to protect granulocytes from apoptosis [34]. In order to test whether increased C3a and C5a receptor signaling was involved in the displayed granulocytosis in \( Cd55^{-/-} \) mice, we assessed circulating granulocyte numbers in \( Cd55^{-/-}C3ar^{-/-}C5ar^{-/-} \) compound mice. Figure 2B shows that CD55-deficient mice still displayed granulocytosis when C3a and C5a receptor signaling was abrogated, indicating that increased granulocyte numbers in the \( Cd55^{-/-} \) mice did not result from enhanced complement receptor activation.

Expanded granulopoietic activity in CD55-deficient and CD97-deficient mice

In order to obtain insight into the mechanism behind the observed granulocytosis, we started out by exploring the total population of mature peripheral granulocytes. These can exist as

**Figure 1. Lack of CD55 causes a mild granulocytosis.** Immune cells obtained from bone marrow, blood, and spleen of wild-type and \( Cd55^{-/-} \) mice were incubated with antibodies against Ly6G (or Gr-1) and CD11b and analyzed by flow cytometry. (A) Representative dot plots showing Gr-1 against CD11b expression on bone marrow-derived cells and Ly6G against CD11b expression on PBL and splenocytes of wild-type and CD55\(^{-/-} \) mice. (B) Percentages (upper panels) and total numbers (lower panels) of mature granulocytes in one femur (CD11b\(^+\)Gr-1\(^{hi}\)), 1 ml blood (CD11b\(^+\)Ly6G\(^+\)), or in total spleen (CD11b\(^+\)Ly6G\(^+\)) of wild-type and \( Cd55^{-/-} \) mice. Circles represent individual mice and horizontal lines indicate the mean of the percentage or absolute number of granulocytes per group (n = 7-35). *, \( p < 0.05 \) and ***, \( p < 0.0005 \) doi:10.1371/journal.pone.0024431.g001
freely circulating cells as well as reversibly adhered cells to the vascular endothelium [35]. The latter so called marginated cells can be released into circulation by epinephrine injection, making them accessible for blood sampling [31]. We found that in response to i.p. application of epinephrine, granulocyte numbers in wild-type mice increased almost 3-fold from $4.6 \times 10^5$ to $13.1 \times 10^5$ cells/ml. 

$Cd55^{-/-}$ mice exhibited a similar increase ($10.0 \times 10^5$ to $23.8 \times 10^5$ cells/ml), resulting in granulocyte counts that again were significantly higher compared to wild-type mice (Figure 3A). The normal epinephrine response seen in mice lacking CD55 suggested that the displayed granulocytosis in these mice is not caused by a defect in margination of granulocytes. Pre-mature mobilization from bone marrow would be another possibility to explain the increased number of granulocytes in circulation [35]. However, when we analyzed blood smears of $Cd55^{-/-}$ mice, we found that almost all granulocytes had a mature, segmented phenotype, and no differences were found between $Cd55^{-/-}$ granulocytes compared to wild-type cells (data not shown).

We next tested the possibility of an increased survival of granulocytes in the periphery in $Cd55^{-/-}$ mice. We started with the assessment of granulocyte apoptosis $ex$ $vivo$ by culturing PBL for 20 h, followed by measuring survival rates using Mitotracker. Both wild-type and $Cd55^{-/-}$ granulocytes displayed a considerable amount of apoptosis, which was not different between the two mouse strains (Figure 3B). Granulocytes are short-lived cells with a half-life in circulation of less than one day under normal conditions [35]; and although $Cd55^{-/-}$ granulocytes did not display an altered apoptosis rate $ex$ $vivo$, it could be possible that they are not cleared from circulation as efficient as in wild-type mice. To assess this possibility, we studied the life span of circulating granulocytes $in$ $vivo$. To this end, dividing granulocytes in the bone marrow were pulse-labeled by a single i.p. injection of BrdU [32], and their kinetics in circulation was determined by measuring Ly6G-positive cells that had incorporated BrdU. We found a comparable transit time for BrdU-positive granulocytes to appear in circulation in wild-type and $Cd55^{-/-}$ mice with a peak percentage at 72 h (Figure 3C, left panel). Also the disappearance of labeled cells from blood was not changed in $Cd55^{-/-}$ mice (Figure 3C, left panel). However, the numbers of BrdU-positive granulocytes in circulation in $Cd55^{-/-}$ mice were significantly...
higher throughout the duration of the experiment (Figure 3C, right panel). We concluded that despite a normal life span in circulation, the amount of granulocytes produced and released from the bone marrow was significantly increased in Cd55\(^{-/-}\) mice. Interestingly, Wang et al. showed that CD97-deficient mice had no altered apoptotic rate but they observed an increased response to daily G-CSF injections, also suggesting greater granulopoietic production [26].

To corroborate the hypothesis that both CD55-deficient and CD97-deficient mice had an increased granulopoietic activity, we studied the proliferative activity of Gr-1-positive cells in the bone marrow by measuring their DNA content [33]. Cd55\(^{-/-}\) mice displayed an increased percentage of cells that were in S or G2/M phase of the cell cycle as compared to wild-type mice (Figure 3D). Of note, side-by-side comparison revealed a similar increase in the percentage of dividing Gr-1-positive cells in the bone marrow in Cd97\(^{-/-}\) mice (Figure 3D). Together, these data suggest that the granulocytosis in the periphery of mice lacking either CD55 or CD97 is caused by an increased granulopoiesis.

Augmented protection against pneumococcal pneumonia in CD55-deficient mice

To determine possible consequences of CD55 deficiency for anti-bacterial host defense, mice were inoculated with a lethal dose of S. pneumoniae \((9 \times 10^4 \text{ CFU})\) and monitored over time. While wild-type mice all died at day 3 after infection (median survival time = 64.5 h), Cd55\(^{-/-}\) lived up till day 5 after infection (median survival time = 111.3 h) (Figure 4A). To obtain insight in how Cd55\(^{-/-}\) mice were protected against lethality during pneumococcal pneumonia, we examined bacterial loads in the lungs and blood 24 h and 48 h after infection (Figure 4B and C). Most notably, at these time points, Cd55\(^{-/-}\) mice had significantly lower bacterial loads in blood. Of the wild-type animals, 75% had positive blood cultures, whereas only 37.5% of the Cd55\(^{-/-}\) blood cultures were positive 24 h after infection. At 48 h, all wild-type mice showed positive blood cultures while in the Cd55\(^{-/-}\) group, only 62.5% showed bacterial outgrowth (Figure 4B). Furthermore, at 48 h, Cd55\(^{-/-}\) mice had slightly lower bacterial loads in their lungs compared to wild-type mice (Figure 4C).

Histopathological examination of lung sections showed no differences in lung inflammation between wild-type and Cd55\(^{-/-}\) animals at 24 h (data not shown) and 48 h after infection (Figure 4D). Also, the local concentration of the pro-inflammatory cytokines TNF\(\alpha\) and IL-1\(\beta\) and the chemokines KC and MIP-2 was not different between wild-type and Cd55\(^{-/-}\) mice at 24 h and 48 h after infection (data not shown). Finally, the amount of phagocytic cells present in infected lungs increased over time, but no difference was found between wild-type and Cd55\(^{-/-}\) mice as...
determined by the amount of myeloperoxidase present in lung homogenates (Figure 4E). To further substantiate the point that migration of Cd55−/− granulocytes to sites of inflammation is normal, we induced sterile peritonitis with 4% thioglycollate in wild-type and Cd55−/− mice. Also in this sterile model of inflammation, we saw comparable accumulation of granulocytes in wild-type and Cd55−/− mice (absolute number of granulocytes in peritoneal exudate = 17.4×10⁶ ± 2.0 and 17.0×10⁶ ± 4.0, respectively).

To test the possibility that Cd55−/− granulocytes were functionally more competent, we examined the production of reactive oxygen species (ROS) upon various stimuli. PMA, zymosan, serum-treated zymosan, or PAF/fMLP was used to stimulate oxygen species (ROS) upon various stimuli. PMA, zymosan, Concentration of myeloperoxidase in lung homogenates of wild-type and Cd55−/− mice. No differences were found with respect to the amount of ROS produced, the time to produce it, or the percentage of granulocytes that produced ROS in response to stimulation (data not shown). We concluded that a better protection from bacteremia due to increased granulocyte numbers rather than qualitative improvement of immunity in the lungs likely reduced lethality from S. pneumoniae in Cd55−/− mice.

**Discussion**

We here provide evidence for a novel role of the complement control protein CD55 in granulocyte homeostasis and antibacterial host defense. CD55-deficient mice display increased numbers of circulating granulocytes. On average, we found twice as many granulocytes in the blood stream, the marginalized pool, and the spleen of Cd55−/− compared to wild-type mice. This mild granulocytosis clearly differs from the marked changes in mice that lack leukocyte adhesion molecules [35]. A comparable phenotype has recently been reported in two independently generated CD97-deficient mice [26,27]. The Kelly laboratory and we found that mice lacking CD97 have about two-fold increased granulocyte numbers in blood and spleen in the steady state. This phenotype was not the result of enhanced bone marrow emigration to the blood neither of reduced clearance of circulating cells. Cd97−/− mice showed a greater response to daily G-CSF treatment, which induces granulopoiesis in the bone marrow [26]. In line with this observation, we here demonstrate increased numbers of Gr-1-positive cells in cell cycle in the bone marrow of both CD55-deficient mice and CD97-deficient mice, indicating a higher granulopoietic activity in both strains.

Several pieces of evidence suggest that the role of CD55 in granulocyte homeostasis relates to its interaction with CD97. Firstly, the granulocytosis in both mouse strains is highly comparable and not further accelerated in compound mice. Secondly, mice lacking CD55 and the receptors for C3a and C5a had granulocyte numbers comparable to CD55-deficient mice, excluding a causal link with exaggerated complement receptor activation in the absence of CD55. Thirdly, as discussed above, both Cd55−/− and Cd97−/− mice displayed enhanced granulopoeitic activity. These data suggest that both molecules through their interaction in bone marrow jointly affect granulocyte homeostasis. How this occurs at the molecular level is currently unknown. Both CD55 and CD97 are differentially expressed during the development of hematopoietic progenitor cells [36,37]; moreover, CD55 is present on stromal cells and can be deposited in the extracellular matrix [1,38]. Thus, the interaction between CD55 and CD97 can be involved in various contacts between hematopoietic progenitors and stromal cells. This concept would fit with recent data suggesting that adhesion GPCRs by facilitating cell and matrix contacts contribute to the proper positioning of developing cells in a variety of organ systems [39–41].

Granulocytes are crucially involved in anti-bacterial host defense. To test whether increased granulocyte number exaggerate the innate response in CD55-deficient mice, we applied an acute model of pneumococcal pneumonia. In response to a lethal dose of S. pneumoniae, Cd55−/− mice displayed a better clearance of bacteria from blood and lung correlating with an extended survival compared to wild-type mice. Increased complement activation in the absence of CD55 may ameliorate this exaggerated response and might explain why a similar protective effect was not found previously by us in Cd97−/− mice [27]. However, Kelly and colleagues reported that Cd97−/− mice are more resistant to Listeria monocytogenes, correlated with a more robust accumulation of granulocytes in the blood and the liver of infected mice [26].

Our study strengthens the view that the interaction with CD97 is a physiologically relevant, complement-independent activity of CD55. Further support for the idea was obtained in a recent study, showing a comparable level of protection from experimental arthritis in Cd55−/− and Cd97−/− mice, which might relate to a role of both molecules in the retention of leukocytes in the inflamed synovium [42]. Of note, Cd55 is the first binding partner that is linked functionally to an adhesion GPCR in vivo [43].

**Acknowledgments**

We would like to thank Dr. Anton T.J. Tool and Prof. Sandrine Florquin for help with performing and analyzing experiments. Prof. Arthur J. Verhoeven, Dr. Timo K. van den Berg, and Dr. Martijn A. Nolte for helpful discussions.

**Author Contributions**

Conceived and designed the experiments: HV TvdP RvL. MM JH. Performed the experiments: HV RH AdV AdB F-QA. Analyzed the data: HV AdV AdB F-QA. Contributed reagents/materials/analysis tools: MM. Wrote the paper: HV JH. Revised the manuscript: RH AdB RvL.

**References**

1. Lublin DM, Atkinson JP (1989) Decay-accelerating factor: biochemistry, molecular biology, and function. Annu Rev Immunol 7: 33–58.

2. Nicholson-Weller A, Wang CE (1994) Structure and function of decay accelerating factor CD55. J Lab Clin Med 123: 485–491.
3. Soohe H, Nangaku M, Ishihashi Y, Wada T, Fujita T, et al. (2001) Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis. J Immunol 167: 2791–2797.
4. Miwa T, Maldonado MA, Zhou L, Sun X, Luo HY, et al. (2002) Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice. Am J Pathol 161: 1077–1086.
5. Lin F, Kaminski HJ, Comte-Fine BM, Wang W, Richmond S, et al. (2002) Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J Clin Invest 110: 1269–1274.
6. Lin F, Salant DJ, Meyerson H, Emanuel AP, Morgan BP, et al. (2004) Respective roles of decay-accelerating factor and CD59 in circumventing glomerular injury in acute nephrotoxic serum nephritis. J Immunol 172: 2636–2642.
7. Lin F, Spencer D, Hatala DA, Levine AD, Medof ME (2004) Decay-accelerating factor deficiency increases susceptibility to dextran sulfate sodium-induced colitis: role for complement in inflammatory bowel disease. J Immunol 172: 3836–3841.
8. Yamada K, Miwa T, Liu J, Nangaku M, Song WC (2004) Critical protection from renal ischemia-reperfusion injury by CD55 and CD59. J Immunol 172: 3869–3875.
9. Liu J, Miwa T, Hilliard B, Chen Y, Lambris JD, et al. (2005) The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med 201: 567–577.
10. Heeger PS, Lalli PN, Lin F, Valujskikh A, Liu J, et al. (2005) Decay-accelerating factor modulates induction of T cell immunity. J Exp Med 201: 1523–1530.
11. Strainic MG, Liu J, Huang D, An F, Lalli PN, et al. (2008) Locally produced complement fragments C5a and C3a provide both constitulatory and survival signals to naïve CD4+ T cells. Immunity 28: 425–435.
12. Loughi MP, Harris CL, Morgan BP, Gallimore A (2006) Holding T cells in check - a new role for complement regulators? Trends Immunol 27: 102–108.
13. Kemeny JP, Atkinson JP (2007) T-cell regulation: with complements from innate immunity. Nat Rev Immunol 7: 9–18.
14. Lea S (2002) Interactions of CD55 with non-complement ligands. Biochem Soc Trans 30: 1014–1019.
15. Lawrence DW, Bruninek WJ, Louin NA, Ludkin DM, Stahl GL, et al. (2003) Antiahesive role of apical decay-accelerating factor (CD55) in human neuronal transmigration across mucosal epithelia. J Exp Med 198: 999–1010.
16. Hamann J, Vogel B, van Schijndel GMW, van Lier RAW (1996) The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J Exp Med 184: 1185–1189.
17. Eichler W, Aust G, Hamann D (1994) Characterization of an early activation-dependent antigen on lymphocytes defined by the monoclonal antibody BL-Ac/F2. Scand J Immunol 39: 111–115.
18. Hamann J, Eichler W, Hamann D, Kerstens HM, Poddighe PJ, et al. (1995) Expression cloning and chromosomal mapping of the leucocyte activation antigen CD97, a new seven-span transmembrane molecule of the secretion receptor superfamily with an unusual extracellular domain. J Immunol 155: 1942–1950.
19. Gray JX, Haino M, Roth MJ, Maguire JE, Jensen PN, et al. (1996) CD97 is a processed, seven-transmembrane, heterodimeric receptor associated with inflammation. J Immunol 157: 5435–5447.
20. Qian YM, Haino M, Kelly K, Song WC (1999) Structural characterization of mouse CD97 and study of its specific interaction with murine decay-accelerating factor (DAF, CD55). Immunology 98: 303–311.
21. Hamann J, van Zeventer C, Bijl A, Molemaa C, Treska k L, et al. (2000) Molecular cloning and characterization of mouse CD97. Int Immunol 12: 439–448.
22. Kwakkenbos MJ, Kop EN, Stacey M, Mattanti M, Geerd s S, et al. (2004) The EGF-TM7 family- a postgenomic view. Immunogenetics 55: 653–666.
23. Hamann J, Stortelers C, Koo-Tooth E, Vogel B, Eichler W, et al. (1998) Characterization of the CD55 (DAF)-binding site on the seven-span transmembrane receptor CD97. Eur J Immunol 28: 1701–1707.
24. Lin HH, Stacey M, Soxy C, Knott V, Chaudhury Y, et al. (2001) Molecular analysis of the epidermal growth factor-like short consensus repeat domain-mediated protein-protein interactions: dissection of the CD97-CD55 complex. J Biol Chem 276: 24160–24169.
25. Leemans JC, te Velde AA, Florquin S, Bennink RJ, de Bruijn K, et al. (2004) The epidermal growth factor-seven transmembrane (EGF-TM7) receptor CD97 is required for neutrophil migration and host defense. J Immunol 172: 1125–1131.
26. Wang T, Tian I, Haino M, Gao JL, Lake R, et al. (2007) Improved antibacterial host defense and altered peripheral granulocyte homeostasis in mice lacking the adhesion class G protein receptor CD97. Infect Immun 75: 1144–1153.
27. Veninga H, Becker S, Hock KM, Wobus M, Wandel E, et al. (2008) Analysis of CD97 expression and manipulation: antibody treatment but not gene targeting curtails granulocyte migration. J Immunol 181: 6574–6583.
28. Lin F, Fukuoka Y, Spicer A, Ohta R, Okada N, et al. (2001) Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Dafl knock-out mouse and site-specific monoclonal antibodies. Immunology 104: 215–225.
29. Humbles AA, La B, Niznik JA, Lilly C, Israel E, et al. (2000) A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 406: 998–1001.
30. Hopken UE, La B, Gerard NP, Gerard C (1996) The C3a chemoattractant receptor mediates mucosal defense to infection. Nature 383: 86–89.
31. Nasirkenari M, Segal BH, Ostberg JR, Urbasic A, Lau JT (2006) Altered granulopoietic profile and exaggerated acute neutrophilic inflammation in mice with targeted deficiency in the sialyltransferase ST6Gal I. Blood 108: 3397–3405.
32. Eash KJ, Means JM, White DW, Link DC (2009) CXCR4 is a key regulator of neutrophil release from the bone marrow under basal and stress granulopoiesis conditions. Blood 113: 4711–4719.
33. Ueda Y, Kondo M, Kelsoo G (2005) Inflammation and the reciprocal production of granolocytes and lymphocytes in bone marrow. J Exp Med 201: 1771–1780.
34. Perianayagam MC, Balakrishnan VS, Pereira BJ, Jaber BL (2004) C5a delays apoptosis of human neutrophils via an extracellular signal-regulated kinase and Bad-mediated signalling pathway. Eur J Clin Invest 34: 50–56.
35. von Viertinghoff S, Ley K (2008) Homostatic regulation of blood neutrophil counts. J Immunol 181: 5183–5188.
36. Terstappen LW, Nguyen M, Lazzar HM, Medof ME (1992) Expression of the DAF (CD55) and CD59 antigens during normal hematopoietic cell differentiation. J Leukoc Biol 52: 652–660.
37. van Pel M, Hageort H, Hamann J, Fibbe WE (2008) CD97 is differentially expressed on murine hematopoietic stem and progenitor cells. Haematologica 93: 1117–1144.
38. Li L, Spendlove I, Morgan J, Durrant LG (2002) CD55 is over-expressed in the tumour environment. Br J Cancer 84: 80–86.
39. Kotzalas S, Jin Z, Piao X, Corfas G (2009) GPR56-regulated granule-cell adhesion is essential for rostral cerebellar development. J Neurosci 29: 7439–7449.
40. Langenhans T, Promel S, Mestek I, Emaeili B, Waller-Evans H, et al. (2009) Latrophilin signaling links anterior-posterior tissue polarity and oriented cell division in the C. elegans embryo. Dev Cell 17: 494–504.
41. Steinem A, Wong L, Najarro EH, Ackley BD, Garriga G, et al. (2010) The Flamingo ortholog FMI-1 controls pioneer-dependent navigation of follower axons in C. elegans. Development 137: 3663–3673.
42. Hock KM, de Launay D, Kop EN, Yilmaz-Elis AS, Lin F, et al. (2010) Deletion of either CD55 or CD97 ameliorates arthritis. Arthritis Rheum 62: 1036–1042.
43. Yona S, Lin HH, Sin WO, Gordon S, Stacey M (2000) Adhesion-GPCRs: emerging roles for novel receptors. Trends Biochem Sci 25: 171–175.

CD55 Controls Granulopoiesis and Host Defense